Original citation: J Clin Invest. 2017;127(7):2777–2788. https://doi.org/10.1172/JCI92958
Citation for this retraction: J Clin Invest. 2024;134(13):e183295. https://doi.org/10.1172/JCI183295
QIMR Berghofer Medical Research Institute recently notified the JCI of concerns regarding Figure 3C and Supplemental Figure 4A and indicated that an independent panel investigation concluded that these figures are based on data fabricated by Mark J. Smyth. In addition, the investigative panel concluded that Figures 3D and 3E are based on unreliable or unconfirmed data produced by Mark J. Smyth. The QIMR Berghofer Medical Research Institute investigation found that one author, Mark J. Smyth, was the sole individual responsible for provision of data in Figure 3, C–E, and Supplemental Figure 4A. Due to these data integrity concerns, the JCI is retracting this article. No issues were raised with regard to any of the other data in the article.
Kevin Kos has agreed with the JCI’s decision to retract the paper. The remaining authors abstained from commenting or could not be reached.
Version 1. 07/01/2024
Electronic publication
Footnotes
See the related article at Natural killer cell heparanase controls tumor invasion and immune surveillance.
Contributor Information
Kevin Kos, Email: k.kos@nki.nl.
Kyohei Nakamura, Email: kyohei.nakamura@qimrberghofer.edu.au.
Liam Town, Email: liam.town@qimrberghofer.edu.au.
Nikola Baschuk, Email: N.Baschuk@latrobe.edu.au.
Fernando Souza-Fonseca-Guimaraes, Email: guimaraes.f@wehi.edu.au.